Immune characterization of pre-clinical murine models of neuroblastoma
Abstract Immunotherapy offers a potentially less toxic, more tumor-specific treatment for neuroblastoma than conventional cytotoxic therapies. Accurate and reproducible immune competent preclinical models are key to understanding mechanisms of action, interactions with other therapies and mechanisms...
Guardado en:
Autores principales: | Emily R. Webb, Silvia Lanati, Carol Wareham, Alistair Easton, Stuart N. Dunn, Tatyana Inzhelevskaya, Freja M. Sadler, Sonya James, Margaret Ashton-Key, Mark S. Cragg, Stephen A. Beers, Juliet C. Gray |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1cd179c8bd0e4a0ba1a1db6fa9ea0186 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Neuroblastoma
por: Fuentes,Luis, et al.
Publicado: (1976) -
Activation of GABA(A) receptors inhibits T cell proliferation.
por: Emma L Sparrow, et al.
Publicado: (2021) -
PARATESTICULAR INVOLVEMENT IN NEUROBLASTOMA
por: Volkan KÖSE, et al.
Publicado: (2021) -
Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse models
por: Nan Li, et al.
Publicado: (2021) -
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Maged Zeineldin, et al.
Publicado: (2020)